Inverness Medical Innovations
This article was originally published in The Gray Sheet
Executive Summary
$56.5 mil. purchase of Abbott Laboratories' Determine and DainaScreen rapid infectious disease diagnostics will provide the Waltham, Mass. firm with a "viable platform" to "solidify our commitment to the Japanese market," Inverness CEO Ron Zwanziger explains May 31. Inverness previously purchased pregnancy, strep throat, and drugs-of-abuse rapid diagnostic test lines from Abbott for international distribution (1"The Gray Sheet" Oct. 6, 2003, p. 20). Determine/DainaScreen generated roughly $23 mil. for Abbott in 2004...
You may also be interested in...
Inverness’ $92.5 Mil. Abbott Rapid Testing Buy Could Return TestPack To U.S.
Abbott Labs will retain exclusive distribution rights for the TestPack and Signify test lines in the U.S., while the products' new owner - Inverness Medical Innovations - will take on international distribution responsibilities
EU Experts Want One-Stop-Shop EU Governance That Mimics Best Of Other Jurisdictions
It may be blue sky thinking to surmise how a new EU medtech regulatory governance structure could evolve. But with change on the horizon, experts see exciting opportunities.
How Ochre Bio Bagged Boehringer For Its RNA-Based Regenerative MASH Therapies
UK-based Ochre Bio has signed its first major deal with Boehringer Ingelheim. Scrip talked to its co-founder and CEO, Jack O’Meara, about its human tissue-based drug discovery platform, its resulting RNA platform for liver disease and how the fledgling drug company's early work mirrored that seen in diagnostics.